CRDA Croda International Plc

TIDMCRDA

RNS Number : 8899E

Croda International PLC

04 July 2023

Regulatory News Release

4 July 2023

Croda successfully completes acquisition of Solus Biotech

Croda International Plc ('Croda') today confirms that, following receipt of unconditional approval from the South Korean regulatory authorities, it has now successfully completed the acquisition of Solus Biotech, a global leader in premium, biotechnology-derived active ingredients for beauty care and pharmaceuticals.

This follows the announcement on 6 February 2023 that Croda had reached an agreement to acquire Solus Biotech.

-ENDS-

Further information:

   Investors: David Bishop, Croda                                              +44 7823 874428 
   Media: Charlie Armitstead, Teneo                                          +44 7703 330269 

About Croda:

Croda is the company that uses smart science to create high performance ingredients and technologies that improve lives. For m ore information see: www.croda.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ACQSSSSWLEDSESW

(END) Dow Jones Newswires

July 04, 2023 03:02 ET (07:02 GMT)

Grafico Azioni Croda (LSE:CRDA)
Storico
Da Apr 2024 a Mag 2024

Grafico Azioni Croda (LSE:CRDA)
Storico
Da Mag 2023 a Mag 2024